3 Newly Listed Pharma Stocks With a Strong Future Roadmap: Corona Remedies, Rubicon Research and Kwality Pharmaceuticals

Corona Remedies Rs 2,038.30, P/E 62.62. Rubicon Research Rs 1,596.80, P/E 91.75. Kwality Pharma Rs 3,745.00, P/E 48.02. Closing prices of 6 Oct 2026.

Newly listed pharma stocks give investors exposure to recent IPO companies that sell branded formulations, specialty generics and export products. Results depend on product launches, prescription growth and operating margin, which is why a visible track record matters as much as headline growth.

This list covers three specialty formulation stocks: Corona Remedies for branded formulations for chronic and acute therapies in India, Rubicon Research for specialty and complex generic formulations for the United States and Kwality Pharmaceuticals for oncology, hormone and other formulations for export markets. Every figure comes from the latest reported financials and the 6 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Newly Listed Pharma Stocks?

Newly listed pharma stocks are shares of drug companies that came to market through IPOs in the last few years. They sell domestic branded formulations, specialty generics and export products, and their results depend on product launches, prescription growth, operating margin and how quickly new capacity is used.

Newly Listed Pharma Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three newly listed pharma stocks as of the 6 October 2026 close.

Among specialty formulation stocks, all three trade at a premium to their industry P/E multiples.

Why Do Newly Listed Pharma Stocks Have a Strong Roadmap in India?

Newly listed pharma stocks have a strong roadmap in India because domestic medicine demand is rising, specialty generics open export markets and IPO funds are paying for capacity and launches. Three drivers stand out.

• Domestic demand: Chronic therapies and insurance cover are lifting prescription volumes.
• Specialty generics: Complex products earn better margins than basic generics.
• IPO funding: Fresh capital supports new plants and product launches.

Corona Remedies: Branded Formulations and Field Force Anchor the Roadmap

Corona Remedies’ roadmap rests on branded formulations for chronic and acute therapies in India, with a wider field force and new launches lifting prescriptions.

FY26 revenue was Rs 1,413.83 crore, 17.6% higher than FY25. FY26 net profit rose 23.9% to Rs 185.12 crore. In Q1 FY27, revenue grew 22.1% to Rs 425.58 crore, and net profit rose 30.1% to Rs 60.11 crore. Operating margin was 20.33% in FY26 and 22.79% in Q1 FY27 against 20.66% a year earlier.

Debt to equity is 0.22 and return on equity is 24.79%. FY26 operating cash flow was Rs 229.48 crore against capital expenditure of Rs 174.13 crore. Corona Remedies paid a dividend of Rs 10 per share for FY26, a yield of 0.49%. At a P/E of 62.62 against an industry P/E of 37.19, the stock trades above its industry multiple.

What to watch: The P/E of 62.62 is well above the industry multiple of 37.19, and FY26 capex of Rs 174.13 Cr took a large share of operating cash flow. The P/E of 62.62 sits above the industry P/E of 37.19, so earnings delivery matters for the valuation.

Rubicon Research: Specialty Formulations for the US Drive the Pipeline

Rubicon Research’s roadmap rests on specialty and complex generic formulations for the United States, with a growing product pipeline supporting revenue.

Revenue grew from Rs 330.42 crore in FY22 to Rs 1,761.68 crore in FY26, a 433.2% rise, and FY26 revenue was 36.8% higher than FY25. FY26 net profit rose 83.6% to Rs 246.74 crore. In Q1 FY27, revenue grew 52.9% to Rs 540.02 crore, and net profit rose 95.8% to Rs 84.78 crore. Operating margin was 23.26% in FY26 and 25.23% in Q1 FY27 against 22.62% a year earlier.

Debt to equity is 0.24 and return on equity is 19.14%. FY26 operating cash flow was Rs 205.05 crore against capital expenditure of Rs 229.17 crore. Rubicon Research paid a dividend of Rs 1.5 per share for FY26, a yield of 0.09%. At a P/E of 91.75 against an industry P/E of 37.19, the stock trades above its industry multiple.

What to watch: The P/E of 91.75 is far above the industry multiple of 37.19, and FY26 capex of Rs 229.17 Cr was above operating cash flow of Rs 205.05 Cr. The P/E of 91.75 sits above the industry P/E of 37.19, so earnings delivery matters for the valuation.

Kwality Pharmaceuticals: Export Formulations and Higher Margins Build the Next Leg

Kwality Pharmaceuticals’ roadmap rests on oncology, hormone and other formulations for export markets, with higher volumes lifting both sales and margins.

Revenue grew from Rs 459.70 crore in FY22 to Rs 505.94 crore in FY26, a 10.1% rise, and FY26 revenue was 36.0% higher than FY25. FY26 net profit rose 69.2% to Rs 67.35 crore. Over four years, net profit moved from Rs 119.94 crore in FY22 to Rs 67.35 crore. In Q1 FY27, revenue grew 45.7% to Rs 162.97 crore, and net profit rose 114.9% to Rs 25.62 crore. Operating margin was 23.91% in FY26 and 25.65% in Q1 FY27 against 22.02% a year earlier.

Debt to equity is 0.39 and return on equity is 20.31%. FY26 operating cash flow was Rs 17.06 crore against capital expenditure of Rs 48.94 crore. At a P/E of 48.02 against an industry P/E of 37.19, the stock trades above its industry multiple.

What to watch: FY26 operating cash flow of Rs 17.06 Cr was well below capex of Rs 48.94 Cr, and FY26 net profit of Rs 67.35 Cr is still below the Rs 119.94 Cr of FY22. The P/E of 48.02 sits above the industry P/E of 37.19, so earnings delivery matters for the valuation.

Best Newly Listed Pharma Stocks in India: Corona Remedies vs Rubicon Research vs Kwality Pharma on Key Financials

Among the best newly listed pharma stocks in India, Kwality Pharma leads on FY26 operating margin and the lowest P/E; Rubicon Research leads on Q1 FY27 revenue growth and five-year revenue growth; Corona Remedies leads on return on equity. The table puts the numbers side by side.

Pharma earnings follow product launches and pricing, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Recent Pharma IPO Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen newly listed pharma stocks and shortlist recent pharma IPO stocks to buy.

1. Compare each stock’s P/E with its industry P/E, which is 37.19 for all three here.
2. Track operating margin across several quarters, because input costs can move faster than prices.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these newly listed pharma stocks

Risks to Consider Before Investing in Newly Listed Pharma Stocks

• Valuation: All three trade above the industry multiple of 37.19.
• Capex: Rubicon Research and Kwality Pharma spent more than operating cash flow on capex in FY26.
• Short listing history: Newly listed firms have a shorter public record to judge.
• Regulatory risk: Plant inspections and approvals can delay launches.

Download the Univest iOS App or Univest Android App to track Corona Remedies, Rubicon Research and Kwality Pharma live.

Final Take: Which Stock Has the Strongest Roadmap?

These three recent pharma IPO stocks cover branded formulations, specialty US generics, and export formulations. Kwality Pharma leads on FY26 operating margin and the lowest P/E; Rubicon Research leads on Q1 FY27 revenue growth and five-year revenue growth; Corona Remedies leads on return on equity.

Across specialty formulation stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the recent pharma IPO stocks to buy discussed here.

FAQs on Newly Listed Pharma Stocks

Which are the best newly listed pharma stocks in India with a strong roadmap?

Ans. Corona Remedies, Rubicon Research and Kwality Pharmaceuticals stand out for their roadmaps in branded and specialty pharma formulations. FY26 revenue growth was 17.6% at Corona Remedies, 36.8% at Rubicon Research and 36.0% at Kwality Pharma, and return on equity ranges from 19.14% to 24.79%.

Is Corona Remedies a good stock to buy now?

Ans. Corona Remedies has a debt to equity ratio of 0.22, a return on equity of 24.79% and a P/E of 62.62 against an industry P/E of 37.19. Valuation, capex and a short listing history move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Corona Remedies, Rubicon Research and Kwality Pharma?

Ans. The P/E ratio is 62.62 for Corona Remedies (industry 37.19), 91.75 for Rubicon Research (industry 37.19) and 48.02 for Kwality Pharma (industry 37.19). All three trade at or above the industry multiple.

Which of these newly listed pharma stocks has the highest return on equity?

Ans. Corona Remedies has the highest return on equity at 24.79%, followed by Kwality Pharmaceuticals at 20.31% and Rubicon Research at 19.14%.

What are the risks of investing in newly listed pharma stocks?

Ans. The main risks are high valuations, capex running ahead of cash flow, a short listing history and regulatory delays. Rubicon Research trades at 91.75 times earnings against an industry multiple of 37.19.

How did Corona Remedies, Rubicon Research and Kwality Pharma perform in Q1 FY27?

Ans. Corona Remedies reported revenue of Rs 425.58 crore, up 22.1% year on year, and net profit rose 30.1% to Rs 60.11 crore. Rubicon Research reported revenue of Rs 540.02 crore, up 52.9% year on year, and net profit rose 95.8% to Rs 84.78 crore. Kwality Pharmaceuticals reported revenue of Rs 162.97 crore, up 45.7% year on year, and net profit rose 114.9% to Rs 25.62 crore.

Do newly listed pharma stocks pay dividends?

Ans. Dividend payouts differ across the three companies. The dividend yield is 0.49% for Corona Remedies, 0.09% for Rubicon Research and 0.00% for Kwality Pharma, based on dividends declared for FY26.

How can I invest in newly listed pharma stocks in India?

Ans. You can buy newly listed pharma stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.